OakChart

Eledon Pharmaceuticals Inc

ELDNHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

2.67-0.09 (-3.26%)
2026-11-11 23:01 CET
Market cap
224.28 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-98.56 USD m
Free cash flow, TTM
-73.86 USD m
EPS diluted, TTM
-0.99
P/E
-
Compare

Price

ELDN against its 20, 50 and 200-day averages
2050200miss
2.003.004.003.1M6.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ELDNclose 2.6720-day 2.5150-day 2.59200-day 3.132.6752w high

40.5% under the 52-week high of 4.49 on 22 Jun 2026. 52-week low 1.35 on 21 Nov 2025. Last 15 sessions, 46.7% high to low

Volume 0.59× normal · the line is the 50-bar volume average

Profile

ELDN
52-week range, 42% of the way up
1.354.49

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The firm also focuses on development of therapy to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L), a biological target with broad therapeutic potential. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

IndexRUT
Employees33
IPOSep 17, 2014
Beta0.96
ATR, 14d0.22
Rel volume0.59
Short float10.26%
Insider own1.02%
Inst own63.14%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap216.97M
Enterprise Value167.70M
Income-98.56M
Sales0.00M
Book/sh0.41
Cash/sh1.09
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees33
IPOSep 17, 2014

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B6.54
P/C2.44
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.90
Current Ratio7.90
Debt/Eq0.01
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.99
EPS next Y-0.83
EPS next Q-0.19
EPS this Y-82.69%
EPS next Y12.63%
EPS next 5Y-17.33%
EPS past 3/5Y55.10% 48.72%
Sales past 3/5Y- -
EPS Y/Y TTM-1475.42%
Sales Y/Y TTM-
EPS Q/Q-91.47%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.-70.89% -

Ownership

Insider Own1.02%
Insider Trans0.00%
Inst Own63.14%
Inst Trans3.04%
ROA-72.74%
ROE-110.71%
ROIC-136.67%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA206.44%
SMA503.20%
SMA200-14.59%
Trades-

Technical

Shs Outstand80.89M
Shs Float80.43M
Short Float10.26%
Short Ratio9.13
Short Interest8.25M
52W High4.49 -40.53%
52W Low1.35 97.78%
Volatility8.96% 9.16%
ATR (14)0.22
RSI (14)52.33
Beta0.96
Rel Volume0.59
Avg Volume903.88K
Volume530,349

Performance

Perf Week-1.11%
Perf Month14.10%
Perf Quarter-27.84%
Perf Half Y-31.19%
Perf YTD76.82%
Perf Year25.35%
Perf 3Y130.17%
Perf 5Y-46.06%
Perf 10Y-98.46%
Recom1.00
Target Price9.50
Prev Close2.76
Price2.67
Change %-3.26%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Jun 18, 2025ResumedHH.C. WainwrightBuy$9+237.1%
Jan 28, 2025InitiatedGGuggenheimBuy$9+237.1%
May 13, 2022ResumedCCantor FitzgeraldOverweight$25 → $15+461.8%
Mar 23, 2021InitiatedCCantor FitzgeraldOverweight$25+836.3%

Peers

Mkt cap
TickerCompanyMkt cap
TNXPTonix Pharmaceuticals Holding Corp75.20M
BMYBristol-Myers Squibb Co128.59B
ZURAZura Bio Ltd137.75M
SNYSanofi ADR115.43B
RNACCartesian Therapeutics Inc209.86M
AMGNAMGEN Inc253.21B
VERAVera Therapeutics Inc2.20B
CDNACaredx Inc4.26B
AMLXAmylyx Pharmaceuticals Inc4.09B
NTRANatera Inc46.38B

Insider trading

6 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
McBride John S.DirectorJan 10 '26Option Exercise0.003,43003,430Jan 16 05:00 PM
Hillson JanDirectorJan 10 '26Option Exercise0.003,43003,430Jan 16 05:00 PM
Kirk AllanDirectorJan 10 '26Option Exercise0.003,43003,430Jan 16 05:00 PM
Katkin KeithDirectorJan 10 '26Option Exercise0.008,57508,575Jan 16 05:00 PM
Lee JuneDirectorJan 10 '26Option Exercise0.003,43003,430Jan 16 05:00 PM
Robinson James A. Jr.DirectorJan 10 '26Option Exercise0.003,43003,430Jan 16 05:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IWCiShares Micro-Cap ETFAUM: 1.22B
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B

News

latest 14 of 200
  • Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting (GlobeNewswire)
  • Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting (GlobeNewswire)
  • Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society (GlobeNewswire) +7.43%
  • Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society (GlobeNewswire)
  • Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 (GlobeNewswire)
  • Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
  • A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up (PR Newswire)
  • The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy (PR Newswire) +7.12%
  • Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial (Business Wire) -7.83%
  • Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus (GlobeNewswire)
  • Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine (GlobeNewswire)
  • Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions (GlobeNewswire) -5.28%
  • Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress (GlobeNewswire) +7.26%
  • Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.270-0.158-0.2700.000.005
2026Q12026-05-13-0.330-0.184-0.3470.000.005
2025Q42026-03-19-0.120-0.203-0.1390.000.006
2025Q32025-11-14-0.210-0.246-0.2260.000.007
2025Q22025-08-14-0.130-0.230-0.1450.000.007
2025Q12025-05-14-0.080-0.263-0.0840.000.003
2024Q42025-03-20-0.640-0.312-0.7460.000.006
2024Q32024-11-12-0.320-0.315-0.3160.000.004
2024Q22024-08-08-0.705-0.304-1.0620.000.005
2024Q12024-05-09-0.340-0.366-0.7880.000.004
2023Q42024-03-28-0.320-0.358-3.5450.000.006
2023Q32023-11-09-0.350-0.461-0.3450.000.006
2023Q22023-08-10-0.400-0.459-0.3990.000.005
2023Q12023-05-11-0.750-0.636-0.7540.000.003
2022Q42023-03-30-4.090-0.633-4.2380.000.004
2022Q32022-11-14-0.730-0.680-0.7340.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-24.480-23.940-24.4250.000.00
2020FY-15.720-6.143-15.7160.000.00
2021FY-2.330-2.578-2.3280.000.00
2022FY-6.160-2.493-6.1580.000.00
2023FY-1.640-1.698-4.7340.000.00
2024FY-0.750-0.702-0.7450.000.00
2025FY-0.520-0.673-0.5200.000.00
2026FY--0.950--0.00
2027FY--0.830--0.00
2028FY--0.840--0.00
2029FY--0.715--18.29
2030FY--0.595--51.95

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-145000.000.000.00
2026Q3S2026-08-135000.000.000.00
2026Q3S2026-05-155000.000.000.00
2026Q3S2026-05-144000.000.000.00
2026Q3S2026-03-263000.000.000.00
2026Q3S2026-03-202000.000.000.00
2026Q3S2025-11-173000.000.000.00
2026Q3S2025-11-112000.000.000.00
2026Q3S2025-11-102000.000.000.00
2026Q3S2025-11-092000.000.000.00
2026Q3S2025-11-082000.000.000.00
2026Q3S2025-11-072000.000.000.00
2026Q3S2025-11-062000.000.000.00
2026Q3S2025-11-052000.000.000.00

Estimate history

EPS, annual-41.4-28.113-24.425-15.716-2.328-6.158-4.734-0.745-0.557-0.9903
Period201720182019202020212022202320242025TTM
EPS, quarterly-1.062-0.316-0.746-0.084-0.145-0.226-0.139-0.347-0.278
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.3950.5230.7215.1614.30713.77724.21359.78975.4380.891
Period201720182019202020212022202320242025MRQ
Shares, quarterly38.50741.18359.78959.88259.88259.88275.4375.85280.891
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.360.370.370.200.180.180.01
Gross Profit0.000.00-0.36-0.37-0.37-0.20-0.18-0.18-0.01
Selling, General and Administrative Excl. Other84.6083.2570.2242.6339.4136.6713.1014.0014.05
Research and Development67.8966.2751.9630.3127.0823.736.138.136.82
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-84.60-83.25-70.58-43.00-39.78-36.87-13.28-14.18-14.06
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense17.49-33.45-30.9076.2148.650.0010.011.87-
Net Income Before Taxes-98.53-45.58-35.75-116.54-87.97-36.86-23.21-16.01-14.06
Income Taxes0.040.040.430.000.00-2.35-0.400.000.00
Consolidated Net Income-98.56-45.62-36.18-116.54-87.97-34.51-22.81-16.01-14.06
Net Income From Continuing Operations-98.56-45.62-36.18-116.54-87.97-34.51-22.81-16.01-14.06
Net Income-98.56-45.62-36.18-116.54-87.97-34.51-22.81-16.01-14.06
EPS (Recurring)-0.76-0.84-1.19-2.57-3.77-2.33-10.89-22.43-28.11
EPS (Basic, Before Extraordinaries)-0.99-0.56-0.75-4.73-6.16-2.33-15.72-24.42-28.11
EPS (Diluted)-0.99-0.56-0.75-4.73-6.16-2.33-15.72-24.42-28.11
EBITDA-84.60-83.25-70.22-42.63-39.41-36.67-13.10-14.00-14.05
Non-Operating Income (Expense)3.574.223.922.670.460.010.080.04-0.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.058.2610.376.548.155.772.311.311.54
Shares Outstanding80.8975.4359.7924.2113.7814.3115.160.720.52
Market Capitalization224.28224.28246.1343.5631.3763.0916.587.5215.08

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.090.08
Gross Profit0.000.000.000.000.000.00-0.09-0.08
Selling, General and Administrative Excl. Other22.8721.1821.4819.0724.7317.9624.6120.43
Research and Development18.2317.2017.4914.9720.2813.5317.9316.52
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-22.87-21.18-21.48-19.07-24.73-17.96-24.70-20.51
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense9.6218.96-10.53-0.56-12.29-10.0620.93-96.44
Net Income Before Taxes-31.63-39.02-10.41-17.46-11.22-6.50-44.1976.97
Income Taxes0.000.000.040.000.000.000.430.00
Consolidated Net Income-31.63-39.02-10.45-17.46-11.22-6.50-44.6254.43
Net Income From Continuing Operations-31.63-39.02-10.45-17.46-11.22-6.50-44.6254.43
Net Income-31.63-39.02-10.45-17.46-11.22-6.50-44.6254.43
EPS (Recurring)-0.22-0.23-0.24-0.23-0.26-0.18-0.50-1.53
EPS (Basic, Before Extraordinaries)-0.28-0.35-0.14-0.23-0.15-0.08-0.751.05
EPS (Diluted)-0.28-0.35-0.14-0.23-0.15-0.08-0.75-0.32
EBITDA-22.87-21.18-21.48-19.07-24.73-17.96-24.61-20.43
Non-Operating Income (Expense)0.861.120.541.051.221.411.441.04
Other After Tax Adjustments0.000.000.000.000.000.000.00-22.54
Stock Option Compensation Expense3.152.200.272.432.692.863.831.78
Shares Outstanding80.8975.8575.4359.8859.8859.8859.7941.18
Market Capitalization224.28233.62113.38155.09162.28203.00246.1398.74

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments133.34140.1851.1056.4184.83114.198.7912.9717.30
Short Term Receivables0.510.000.000.000.000.110.240.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets1.843.555.033.113.511.320.941.301.70
Total Current Assets135.69143.7356.1359.5288.35115.639.9714.2819.00
Net Property, Plant & Equipment0.610.930.360.740.770.140.320.010.03
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets32.3932.3932.3932.3981.0348.650.001.871.87
Deferred Tax Assets68.5952.0436.83------
Other Assets0.320.360.190.150.4032.770.640.870.00
Total Assets237.60229.44125.8992.79170.55197.1910.9317.0320.89
Short Term Debt Incl. Current Port. of LT Debt0.360.310.380.360.370.140.180.000.00
Accounts Payable3.635.830.972.201.811.370.330.690.42
Other Current Liabilities14.365.432.543.912.220.970.811.841.02
Total Current Liabilities18.3411.583.906.474.402.481.322.531.44
Long Term Debt0.280.640.000.380.400.000.140.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities70.7854.2238.581.751.754.11---
Other Liabilities11.4244.8776.210.000.000.000.000.000.00
Total Liabilities100.82111.30118.698.616.556.591.472.531.44
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value55.690.000.000.000.000.000.000.000.00
Common Equity81.08118.147.2184.18164.00190.609.4614.4919.45
Total Shareholders Equity136.78118.147.2184.18164.00190.609.4614.4919.45
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity136.78118.147.2184.18164.00190.609.4614.4919.45
Total Liabilities & Stockholders Equity237.60229.44125.8992.79170.55197.1910.9317.0320.89
Book Value Per Share1.071.980.306.1111.4612.5713.1427.6949.24
Tangible Book Value Per Share0.651.43-1.043.765.809.3613.1424.1244.52
Full-Time Employees3331201712108107
Price to Book Ratio6.762.230.460.220.381.220.791.041.37
Return on Assets-19.53-20.37-106.58-66.81-18.77-21.92-114.54-74.19-42.56
Return on Equity-35.79-57.73-255.03-70.89-19.46-22.80-133.66-82.87-46.55
Return on Invested Capital-33.28-30.46-1,616.77-104.02-20.99-11.97-166.63-97.05-55.41
Quick Ratio7.4012.4214.419.1920.0746.577.545.6313.19
Current Ratio7.4012.4214.419.1920.0746.577.545.6313.19

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-98.56-45.62-36.18-116.54-87.97-34.51-22.81-16.01-14.06
Depreciation--0.360.370.370.200.180.180.01
Other Funds (Non Cash)26.74-24.38-20.5981.5556.807.908.003.171.54
Funds from Operations-71.82-69.99-55.98-34.61-30.79-28.76-15.03-12.65-12.51
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-2.047.658.71-4.922.37-0.15-0.18-1.200.62
Cash from Operating Activities-73.86-62.34-47.27-39.53-28.42-28.91-15.21-13.86-11.89
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments21.1410.79-70.31-45.290.000.000.000.000.00
Purchase of Investments-161.26-161.13-156.13-78.290.000.000.000.000.00
Sale Or Maturity of Investments182.40171.9385.8233.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.0011.040.000.00
Cash from Investing Activities21.1410.79-70.31-45.290.000.0011.040.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock53.7853.81133.5233.020.00-0.45109.619.687.56
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock53.7853.81133.5233.020.00-0.45109.619.687.56
Proceedsfrom Stock Options0.000.000.0033.020.00-0.45104.239.687.49
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00-0.030.000.00
Other Financing Activities Uses0.000.000.000.000.000.00-0.030.000.00
Cash from Financing Activities53.7853.81133.5233.020.00-0.45109.589.687.56
Net Change in Cash1.062.2615.94-51.80-28.42-29.36105.40-4.18-4.33
Free Cash Flow-73.86-62.34-47.27-39.53-28.42-28.91-15.21-13.86-11.89
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.010.430.000.00-2.35-0.400.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments88.76111.09133.3493.40107.57124.88
Short Term Receivables0.430.580.510.750.700.76
Inventories0.000.000.000.000.000.00
Other Current Assets3.911.901.842.153.132.08
Total Current Assets93.09113.57135.6996.30111.40127.72
Net Property, Plant & Equipment0.450.530.610.690.770.85
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets32.3932.3932.3932.3932.3932.39
Deferred Tax Assets--68.59---
Other Assets0.170.180.320.480.350.35
Total Assets126.09146.67237.60129.86144.91161.31
Short Term Debt Incl. Current Port. of LT Debt0.380.370.360.350.340.33
Accounts Payable3.216.583.634.635.832.90
Other Current Liabilities8.196.5014.369.327.555.96
Total Current Liabilities11.7913.4618.3414.3013.729.19
Long Term Debt0.090.190.280.380.470.56
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities2.192.1970.782.182.182.18
Other Liabilities40.0030.3811.4221.9522.5134.80
Total Liabilities54.0646.21100.8238.8038.8846.73
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value39.0255.6955.6955.6955.690.00
Common Equity33.0144.7681.0835.3650.33114.58
Total Shareholders Equity72.03100.46136.7891.05106.03114.58
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity72.03100.46136.7891.05106.03114.58
Total Liabilities & Stockholders Equity126.09146.67237.60129.86144.91161.31
Book Value Per Share0.410.591.070.590.841.91
Tangible Book Value Per Share0.010.160.650.050.301.37
Full-Time Employees--33---
Price to Book Ratio6.762.872.563.081.421.72
Return on Assets-72.74-50.75-19.53-65.28-5.95-34.35
Return on Equity-110.71-72.68-35.79-95.49-16.20-83.30
Return on Invested Capital-43.86-38.78-7.62-19.10-10.53-5.64
Quick Ratio7.908.447.406.748.1213.91
Current Ratio7.908.447.406.748.1213.91

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-31.63-39.02-10.45-17.46-11.22-6.50
Other Funds (Non Cash)12.5720.79-8.311.69-9.95-7.81
Funds from Operations-19.06-18.24-18.75-15.77-21.17-14.31
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-3.61-4.374.661.293.46-1.75
Cash from Operating Activities-22.68-22.61-14.09-14.48-17.71-16.06
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments23.245.96-20.4612.4014.963.89
Purchase of Investments-16.26-43.12-69.22-32.66-27.40-31.85
Sale Or Maturity of Investments39.5049.0848.7645.0642.3635.74
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities23.245.96-20.4612.4014.963.89
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.090.0053.690.000.000.12
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.090.0053.690.000.000.12
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.090.0053.690.000.000.12
Net Change in Cash0.65-16.6619.14-2.07-2.75-12.05
Free Cash Flow-22.68-22.61-14.09-14.48-17.71-16.06

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.26%8.3M80.4M931.74K
2026-10-159.82%7.9M80.4M912.48K
2026-09-309.76%7.8M80.4M1.02M
2026-09-1510.27%8.3M80.4M1.27M
2026-08-319.64%7.7M80.4M1.28M
2026-08-147.82%6.3M80.4M1.28M
2026-07-318.23%6.2M75.5M1.34M
2026-07-157.49%5.5M73.8M1.54M
2026-06-3010.62%7.8M73.8M1.52M
2026-06-1510.17%7.5M73.8M1.41M
2026-05-299.88%7.3M73.7M1.46M
2026-05-159.20%6.8M73.7M1.46M
2026-04-3010.51%7.6M71.9M1.34M
2026-04-1510.87%7.8M71.9M1.08M
2026-03-3110.01%7.2M71.8M1.02M
2026-03-1311.84%8.4M71.1M854.51K
2026-02-279.08%6.5M71.1M805.65K
2026-02-138.98%6.4M71.1M1.11M
2026-01-309.13%6.4M70.0M1.89M
2026-01-159.03%6.3M70.0M2.15M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.902.700.000.0000.000.000.976-0.0110.000
call1.001.352.250.0014.1270.000.000.954-0.0380.000
call1.500.851.800.009.7340.000.000.880-0.0500.001
call2.000.351.300.006.7280.000.000.795-0.0490.001
call2.500.300.350.321.9162,96914.000.671-0.0380.002
call5.000.000.050.012.6533,6260.000.108-0.0120.001
call7.500.000.050.033.6241,3060.000.083-0.0130.001
put0.500.000.050.007.6110.000.00-0.023-0.0100.000
put1.000.000.950.0016.8040.000.00-0.046-0.0380.000
put1.500.000.950.0010.5760.000.00-0.120-0.0500.001
put2.000.000.750.007.3320.000.00-0.205-0.0490.001
put2.500.000.700.145.0103660.00-0.329-0.0380.002
put5.001.752.752.155.6491.000.00-0.893-0.0110.001
put7.504.705.005.245.3166.000.00-0.916-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-30SCHEDULE 13G/ASEC
2026-09-04S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-08-044Statement of changes in beneficial ownership of securities2026-07-31SEC
2026-07-31SCHEDULE 13GSEC
2026-06-228-KCurrent report2026-06-18SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-11EFFECTEffectiveness filing by commission orderSEC
2026-05-07CORRESPSEC
2026-05-07UPLOADUpload SubmissionSEC
2026-05-01S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-04-27SCHEDULE 13GSEC
2026-04-21PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-03-26SCHEDULE 13G/ASEC
2026-03-1910-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-198-KCurrent report2026-03-19SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-13SCHEDULE 13G/ASEC
2026-01-21SCHEDULE 13G/ASEC
2026-01-164Statement of changes in beneficial ownership of securities2026-01-10SEC
2026-01-164Statement of changes in beneficial ownership of securities2026-01-10SEC
2026-01-164Statement of changes in beneficial ownership of securities2026-01-10SEC
2026-01-164Statement of changes in beneficial ownership of securities2026-01-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BVF INC/IL8.15%
BlackRock, Inc.6.64%
Defilade Capital Management, L.P.4.57%
VANGUARD CAPITAL MANAGEMENT LLC4.43%
GOLDMAN SACHS GROUP INC3.25%
Ensign Peak Advisors, Inc2.72%
GEODE CAPITAL MANAGEMENT, LLC2.44%
Catalio Capital Management, LP2.20%
STATE STREET CORP2.10%
Zimmer Partners, LP2.07%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND3.22%
iShares Russell 2000 ETF2.64%
VANGUARD EXTENDED MARKET INDEX FUND1.11%
Fidelity Small Cap Index Fund1.09%
iShares Russell 2000 Growth ETF0.94%
VANGUARD RUSSELL 2000 INDEX FUND0.54%
Fidelity Extended Market Index Fund0.45%
Goldman Sachs Small Cap Equity Insights Fund0.40%
Goldman Sachs Small Cap Value Insights Fund0.37%
iShares Micro-Cap ETF0.33%

OakChart. ELDN. Cached 15 minutes.